The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $175.28

Today's change0.00 0.00%
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $175.28

Today's change0.00 0.00%
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc closed at (U.S.)$175.28.

Over the last five days, shares have lost 2.52% and are down 5.27% for the last year to date. This security has outperformed the S&P 500 by 5.61% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $175.28
  • High--
  • Low--
  • Bid / Ask(U.S.) $168.00 / (U.S.) $172.00
  • YTD % change-5.27%
  • Volume7
  • Average volume (10-day)2,128,429
  • Average volume (1-month)1,568,818
  • Average volume (3-month)1,842,441
  • 52-week range(U.S.) $150.06 to (U.S.) $208.88
  • Beta0.67
  • Trailing P/E59.89×
  • P/E 1 year forward36.16×
  • Forward PEG2.15×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.93
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+24.78%

Based on its net profit margin of 24.78%, Alexion Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue636600599555
Total other revenue--------
Total revenue636600599555
Gross profit584531550503
Total cost of revenue52694952
Total operating expense455497396318
Selling / general / administrative221187184158
Research & development12621612597
Depreciation / amortization6543
Interest expense (income), net operating--------
Unusual expense (income)5019338
Other operating expenses, total--------
Operating income181104204237
Interest income (expense), net non-operating---1-1--
Gain (loss) on sale of assets--------
Other--------
Income before tax177107205236
Income after tax17091153178
Income tax, total7165258
Net income17091153178
Total adjustments to net income--------
Net income before extra. items17091153178
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items17091153178
Inc. avail. to common incl. extra. items17091153178
Diluted net income17091153178
Dilution adjustment------0
Diluted weighted average shares205202202201
Diluted EPS excluding extraordinary itemsvalue per share0.830.450.760.88
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.070.530.880.91